Literature DB >> 22454934

The effect of frusemide on indomethacin plasma levels.

P M Brooks1, M A Bell, P Lee, P J Rooney, W C Dick.   

Abstract

1 The pharmacokinetic and clinical effects of concurrent oral indomethacin and frusemide administration were determined in eight patients with rheumatoid arthritis. 2 Oral frusemide significantly reduces the plasma level of indomethacin following concurrent administration of the two drugs orally. 3 A profile of pain index, articular index and grip strength following oral indomethacin (50 mg) was determined and although the decrease in articular index was less when frusemide and indomethacin were given together it did not reach statistical significance.

Entities:  

Year:  1974        PMID: 22454934      PMCID: PMC1402534          DOI: 10.1111/j.1365-2125.1974.tb01698.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  DIAGNOSTIC criteria for rheumatoid arthritis: 1958 revision by a committee of the American Rheumatism Association.

Authors: 
Journal:  Ann Rheum Dis       Date:  1959-03       Impact factor: 19.103

2.  An assessment of grip strength measurement in rheumatoid arthritis.

Authors:  P Lee; A Baxter; W C Dick; J Webb
Journal:  Scand J Rheumatol       Date:  1974       Impact factor: 3.641

3.  Observations on drug prescribing in rheumatoid arthritis.

Authors:  P Lee; S J Ahola; D Grennan; P Brooks; W W Buchanan
Journal:  Br Med J       Date:  1974-03-09

4.  The effect of aspirin on serum indomethacin.

Authors:  G D Champion; H E Paulus; E Mongan; R Okun; C M Pearson
Journal:  Clin Pharmacol Ther       Date:  1972 Mar-Apr       Impact factor: 6.875

5.  Furosemide concentrations in serum and urine, and its binding by serum proteins as measured fluorometrically.

Authors:  A W Forrey; B Kimpel; A D Blair; R E Cutler
Journal:  Clin Chem       Date:  1974-02       Impact factor: 8.327

6.  Pharmacokinetics of orally administered furosemide.

Authors:  M R Kelly; R E Cutler; A W Forrey; B M Kimpel
Journal:  Clin Pharmacol Ther       Date:  1974-02       Impact factor: 6.875

7.  Simultaneous pharmacokinetics of indomethacin in serum and synovial fluid.

Authors:  H W Emori; G D Champion; R Bluestone; H E Paulus
Journal:  Ann Rheum Dis       Date:  1973-09       Impact factor: 19.103

8.  Indomethacin: plasma concentrations and protein binding in man.

Authors:  E Hvidberg; H H Lausen; J A Jansen
Journal:  Eur J Clin Pharmacol       Date:  1972-03       Impact factor: 2.953

9.  The renal excretion of indomethacin and its inhibition by probenecid.

Authors:  M D Skeith; P A Simkin; L A Healey
Journal:  Clin Pharmacol Ther       Date:  1968 Jan-Feb       Impact factor: 6.875

10.  Method for assessing therapeutic potential of anti-inflammatory antirheumatic drugs in rheumatoid arthritis.

Authors:  P Lee; J Webb; J Anderson; W W Buchanan
Journal:  Br Med J       Date:  1973-06-23
View more
  4 in total

1.  Influence of chronic diflunisal treatment on the plasma levels, metabolism and excretion of indomethacin.

Authors:  L O Eriksson; E Wåhlin-Boll; H Liedholm; P Seideman; A Melander
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 2.  Osteoarthritis in the aged. Epidemiological issues and optimal management.

Authors:  F M Cicuttini; T D Spector
Journal:  Drugs Aging       Date:  1995-05       Impact factor: 3.923

3.  Clinical Pharmacokinetics of indomethacin.

Authors:  L Helleberg
Journal:  Clin Pharmacokinet       Date:  1981 Jul-Aug       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs.

Authors:  R K Verbeeck; J L Blackburn; G R Loewen
Journal:  Clin Pharmacokinet       Date:  1983 Jul-Aug       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.